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ABSTRACT 35 
Dysregulated cellular metabolism is a hallmark of cancer. As yet, few druggable 36 
oncoproteins directly responsible for this hallmark have been identified. Increased fatty 37 
acid acquisition allows cancer cells to meet their membrane biogenesis, ATP, and 38 
signaling needs. Excess fatty acids suppress growth factor signaling and cause 39 
oxidative stress in non-transformed cells, but surprisingly not in cancer cells. Molecules 40 
underlying this cancer adaptation may provide new drug targets. Here, we identify 41 
Diacylglycerol O-acyltransferase 1 (DGAT1), an enzyme integral to triacylglyceride 42 
synthesis and lipid droplet formation, as a frequently up-regulated oncoprotein allowing 43 
cancer cells to tolerate excess fatty acids. DGAT1 over-expression alone induced 44 
melanoma in zebrafish melanocytes, and co-operated with oncogenic BRAF or NRAS 45 
for more rapid melanoma formation. Mechanistically, DGAT1 stimulated melanoma cell 46 
growth through sustaining mTOR kinase–S6 kinase signaling and suppressed cell death 47 
by tempering fatty acid oxidation, thereby preventing accumulation of reactive oxygen 48 
species including lipid peroxides. 49 
 50 
SIGNIFICANCE  51 
We show that DGAT1 is a bona fide oncoprotein capable of inducing melanoma 52 
formation and co-operating with other known drivers of melanoma. DGAT1 facilitates 53 
enhanced fatty acid acquisition by melanoma cells through suppressing lipototoxicity. 54 
DGAT1 is also critical for maintaining S6K activity required for melanoma cell growth.  55 
 56 
 57 
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INTRODUCTION 58 
The continuous growth and survival of cancer cells is underpinned by dysregulated 59 
cellular metabolism (1). Dysregulated cellular metabolism further promotes cancer 60 
progression by reprogramming stromal cells, mediating evasion of immune responses, 61 
and promoting metastasis (2-4). A central facet of cancer cell metabolism is a shift in 62 
glucose usage away from oxidative phosphorylation towards biosynthetic reactions. 63 
Without compensation by fatty acid oxidation (FAO) and glutaminolysis, this shift would 64 
result in deficiencies in citric acid cycle intermediates needed for ATP production (1).  65 
Although catabolism of fatty acids (FA) is needed to maintain ATP production, 66 
increased lipogenesis (lipid generation) is simultaneously required for cell membrane 67 
synthesis for which FA are principal building blocks (5). Furthermore, lipid signaling 68 
molecules such as phosphatidyl inositides, diacylglycerides (DAG), lysophosphatidic 69 
acid, and prostaglandins implicated in multiple cancer hallmarks (6) also require FA. To 70 
satisfy these competing demands for FA, cancer cells increase its supply. This can be 71 
achieved by initiation of de novo FA synthesis, normally a function of adipocytes and 72 
hepatocytes, but an acquired characteristic of many cancer cells driven by elevated FA 73 
synthase (FASN) expression (5). Alternatively, the additional FA needed can be 74 
scavenged from the blood circulation as well as from abutting adipose tissue. Cancer 75 
cells utilize secreted lipases such as lipoprotein lipase (LPL) to hydrolyze FA from 76 
circulating triglycerides and FA transporter proteins (FATP) such as CD36 and the 77 
SLC27 family of FATP and FA binding proteins (FABP) to facilitate uptake (7). 78 
Enhanced uptake of extracellular FA by cancer cells has been established to promote 79 
tumor growth and dissemination (8-10). Intracellular lipases can also be called on to 80 
liberate FA from intracellular lipid stores, both through lipophagy or otherwise (11). One 81 
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such lipase, monoacylglycerol lipase (MAGL) is up-regulated in some aggressive 82 
cancers, wherein its suppression impedes tumor growth and metastasis (12).  83 
Regardless of the mechanism of acquisition, high levels of free FA come at a 84 
cost to most cells. Non-adipose, untransformed cells that become overloaded with FA 85 
display a constellation of effects termed lipotoxicity, characterized by reduced insulin 86 
signaling (insulin resistance) and increased cell death (13). Multiple processes underlie 87 
lipotoxicity, including increased ceramide synthesis, dysregulation of phospholipid 88 
production that compromises mitochondrial and endoplasmic reticulum (ER) membrane 89 
integrity, induction of reactive oxygen species (ROS), and impairment of ATP 90 
generation (13). How, therefore, dysregulated metabolism favoring FA accumulation is 91 
tolerated by cancer cells, and in particular how the toxic by-products of rampant FA 92 
metabolism (principally reactive oxygen species [ROS] including lipid peroxides) are 93 
suppressed or neutralized, is currently unclear. Targeting the ability of cancer cells to 94 
manage potentially cytotoxic metabolites that arise from the rewiring of metabolic 95 
pathways is an intriguing therapeutic avenue warranting further exploration (1). 96 
Bona fide oncoproteins (defined as gene products whose up-regulation or coding 97 
alteration contributes directly to neoplasia), for example BCR-ABL, BRAFV600E or mutant 98 
EGFR, are highly desirable molecular targets for precision treatment in cancers. Very 99 
few druggable oncoproteins have been identified that are directly responsible for 100 
dysregulating cellular metabolism. Among metabolic enzymes, only point mutations in 101 
the isocitrate dehydrogenases IDH1 and IDH2 have been confirmed as oncogenic 102 
drivers, but these mutations are detected in only 0.9%-3% of all cancers (14) 103 
(Supplementary Figure 1A). While the gene encoding FASN is frequently amplified in 104 
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cancer (Supplementary Figure 1A), FASN inhibitors have so far failed to gain clinical 105 
approval (15). Much of the metabolic reprogramming of cancer cells is achieved through 106 
up-regulation of transcription factors including HIF1, MYC, peroxisome proliferator-107 
activated receptors (PPARs) and sterol regulatory element binding factors (SREBFs) 108 
(16,17). However, these either lack druggable pockets or have diverse physiological 109 
effects, detracting from their therapeutic potential. Thus, there is currently a dearth of 110 
metabolism oncoproteins to pursue as therapeutic targets.  111 
The small, fresh-water, tropical fish Danio rerio, commonly known as zebrafish, 112 
has been embraced as a model for melanoma oncogene discovery and validation (18). 113 
Previously, using zebrafish melanoma models, we identified a progression-associated 114 
transcript signature enriched for lipid metabolism genes and we established enhanced 115 
FA uptake as a characteristic of melanoma, driven in part by LPL (19). Here, we identify 116 
frequent amplification and up-regulation of the gene encoding Diacylglycerol O-117 
acyltransferase 1 (DGAT1) in melanoma, among other cancers. DGAT1 is an ER-118 
resident enzyme that catalyzes the final step in triacylglyceride (TAG) synthesis from 119 
diacylglyceride (DAG) and FA. DGAT1 is required for the formation of lipid droplets 120 
(LD), cytosolic organelles comprising a core of neutral lipids (mainly triglycerides and 121 
sterol esters) delimited by a monolayer of phospholipids, found in multiple cell types 122 
(20). Furthermore, we demonstrate the ability of DGAT1 to induce melanoma formation 123 
in zebrafish, and that DGAT1 exerts its oncogenic effect through shielding melanoma 124 
cells from lipotoxicity, while enhancing cell growth through sustaining mTOR–S6K 125 
signaling. As DGAT1 has been mooted as a clinical target for combating obesity, 126 
several potent and selective small molecule inhibitors are already available for 127 
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repurposing (21) and we demonstrate their ability to suppress melanoma cell growth 128 
and survival. 129 
 130 
RESULTS 131 
Amplification and up-regulation of DGAT1 associates with poor prognosis in 132 
melanoma and multiple other cancers 133 
CD36, FATP1 and LPL that increase FA uptake into melanoma cells (9,19,22) are rarely 134 
activated by point mutation, nor are the genes encoding them often amplified in cancer, 135 
albeit that CD36 amplification is enriched in established cancer cell lines 136 
(Supplementary Figure 1A). Given the lack of metabolism oncoproteins to pursue as 137 
therapeutic targets and the significance of lipid metabolism for melanoma development 138 
(23), we further interrogated the lipid metabolism genes that we previously identified 139 
accompany progression of mutant RAS driven melanoma in zebrafish (19). We plotted 140 
their expression fold-change against association of expression of the human homologue 141 
with patient survival. dgat1a/DGAT1 emerged as an outlier, being both highly up-142 
regulated in zebrafish melanoma and significantly associated with reduced patient 143 
survival (Figure 1A, B). In contrast, expression of the gene encoding the functionally 144 
related, although structurally distinct, Dgat2/DGAT2 (20) did not change significantly nor 145 
associate with patient survival (Figure 1A, B), indicating a possible unique function for 146 
DGAT1 in melanoma. Furthermore, we confirmed elevated expression of human 147 
DGAT1 in melanoma tumors relative to both skin and nevi (Figure 1C) and elevated 148 
DGAT1 protein in human melanoma cell lines relative to primary melanocytes 149 
irrespective of NRAS or BRAF mutational status (Figure 1D). 150 
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We next considered what might underlie DGAT1 up-regulation in melanoma. 151 
Visualization of structural alterations of the DGAT1 gene in The Cancer Genome Atlas 152 
firehose legacy cutaneous melanoma data set using cBioPortal revealed significant 153 
focal amplification (as defined by the stringent GISTIC 2.0 algorithm) in up to 7 % of 154 
melanoma cases with available copy number variation (CNV) data (but revealed no 155 
microscale-aberrations). This frequency of focal amplification was comparable to that for 156 
other recognized melanoma oncogenes (namely CCND1, KIT, CDK4, MITF, TERT and 157 
MDM2; Figure 1E). An extra copy of the long-arm of chromosome 8 (8q), which 158 
contains the DGAT1 locus, but also other putative melanoma oncogenes ASAP1/DDEF, 159 
MYC and GDF6 (24-26) (Figure 1F), has been observed in approximately 30 % of 160 
melanoma cases (27). Consistently, DGAT1, ASAP1, MYC and GDF6 are co-amplified 161 
in melanoma and other cancers (Supplementary Figure 1B, C), although there were 162 
examples where each alone is amplified. However, of these four, high DGAT1 mRNA 163 
expression displayed the strongest association with reduced patient survival (Figure 1B 164 
and Supplementary Figure 1D).  165 
Further arguing for the significance of DGAT1 amplification in melanoma 166 
development, our previous comparative oncogenomic analysis (24) uncovered 167 
amplification of dgat1a together with gdf6b (both on chromosome 19) in oncogenic-168 
BRAF driven zebrafish melanoma, concomitant with up-regulation of dgat1a and gdf6b 169 
mRNA (Figure 1G and Supplementary Table 1). In contrast, neither dgat1b nor gdf6a on 170 
chromosome 16, nor any myc or asap1 paralogues (on chromosomes 2 and 24) were 171 
amplified or up-regulated (Figure 1G, Supplementary Figure 1E, and Supplementary 172 
Table 1). 173 
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Finally, we found DGAT1 to be amplified in other human cancers arising from 174 
distinct cell lineages, a feature of other well-characterized oncogenes, most notably in 175 
up to 26% of cases of ovarian cancer (Supplementary Figure 1F). Strikingly, DGAT1 176 
amplification was associated with significantly poorer progression-free survival across 177 
multiple cancer types (Figure 1H). Thus, from a cancer genomics perspective, DGAT1 178 
exhibits several hallmarks of an oncogene. 179 
 180 
Dgat1 functions as an oncoprotein in zebrafish melanocytes 181 
In human melanoma, DGAT1 amplification was observed to co-occur with BRAF and 182 
NRAS modification, but also independently of either (Figure 2A). To elucidate further the 183 
oncogenic potential of DGAT1, we utilized a melanocyte rescue and lineage restricted 184 
expression system as described previously (24,28). Remarkably, we found that Dgat1a 185 
over-expression in zebrafish melanocytes lacking functional p53 was sufficient to induce 186 
melanoma (Figure 2B), an outcome that we have only previously observed using the 187 
potent well-established oncogenes RAS and BRAF. Moreover, Dgat1a over-expression 188 
cooperated with both oncogenic BRAF and NRAS to accelerate the development of 189 
nodular tumors (Figure 2C-E and Supplementary Figure 2A). Thus, in zebrafish, Dgat1 190 
behaves as a melanoma oncoprotein. Significantly, Dgat2 over-expression was 191 
indistinguishable from the non-oncogenic EGFP control (Figure 2D), indicating that 192 
Dgat1-mediated tumorigenesis is specific and cannot be replicated by the functionally 193 
related Dgat2.  194 
To enable the development of hypotheses explaining how DGAT1 is a potent 195 
oncogene, we investigated the gene expression profile of melanoma tumors over-196 
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expressing Dgat1a, utilizing RNA sequencing (RNA-seq). RNA-seq revealed an 197 
average 5.5-fold increase in dgat1a mRNA expression compared to control EGFP-198 
expressing tumors (Figure 2F). Principal component analysis (Supplementary Figure 199 
2B) and. hierarchical clustering (Supplementary Figure 2C) revealed patterns of gene 200 
expression clearly distinguishing Dgat1a over-expressing tumors from EGFP-201 
expressing tumors. To pinpoint the biological processes providing context for selection 202 
of DGAT1 up-regulation or that are potentially driven by DGAT1 up-regulation, we 203 
compared the gene sets enriched in Dgat1a over-expressing tumors to those enriched 204 
in the TCGA NRASmut DGAT1high melanoma cohort compared to the rest of the NRASmut 205 
tumor samples in the dataset (Figure 2G and Supplementary Figure 2E and 206 
Supplementary Table 2). The overlap in enriched gene sets was only modest (Figure 207 
2G) consistent with very few differentially expressed genes being shared in common 208 
(Supplementary Figure 2F). However, this was not altogether unexpected given that the 209 
genes whose expression most strongly correlated with DGAT1 expression in human 210 
tumors consistently mapped to chromosome 8q (data not shown) and were therefore 211 
likely co-amplified with DGAT1, while dgat1a up-regulation in the zebrafish was driven 212 
by randomly integrated transgene combined with expression of endogenous dgat1a on 213 
a linkage group distinct from human 8q. Nonetheless, we hypothesized that the 214 
conserved gene sets (Supplementary Table 2) would be the most relevant to 215 
understanding the oncogenic role of DGAT1. Intriguingly, numerous of these conserved 216 
gene sets indicated enhanced activation of mTOR signaling and protein translation, as 217 
well as enhanced glycolysis and lipogenesis (Figure 2H), collectively indicative of 218 
increased insulin sensitivity in tumors with up-regulated dgat1a/DGAT1. From this 219 
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analysis, therefore, we hypothesize that DGAT1 up-regulation modulates several 220 
biochemical hallmarks of cancer which are conserved in both zebrafish and human 221 
melanoma.  222 
 223 
DGAT1 enzymatic activity facilitates ribosomal protein S6-kinase (S6K)-224 
stimulated growth 225 
To ascertain which of the key oncogenic pathways highlighted by RNA-seq analysis of 226 
tumors may be directly dependent on DGAT1, we examined the initial signaling 227 
changes that occur when DGAT1 activity is suppressed, by performing unbiased 228 
quantitative mass-spectrometry (MS)-based phospho-proteomics. We analysed 229 
phosphorylated peptides from Stable Isotope Labelling in Cell Culture (SILAC)-labelled 230 
DGAT1high A375 melanoma cells following 4h treatment with A922500. This revealed 231 
that DGAT1 activity affects cell growth and division signaling at mTOR, S6K and CDK1 232 
signaling nodes (Figure 3A and Supplementary Figure 3A), mirroring the enrichment of 233 
the mTOR and protein translation signatures revealed by gene set enrichment analysis 234 
(Figure 2H). Western blotting to detect phosphorylated S6 and eEF2 confirmed that 235 
DGAT1 inhibition led to rapid loss of mTOR and S6K activities in multiple melanoma cell 236 
lines with up-regulated expression of endogenous DGAT1, including LOXIMVI and 237 
SKMEL5 that harbor DGAT1 amplification (Figure 3B and Supplementary Figure 3B). 238 
This effect was not observed with DGAT2 inhibition (Supplementary Figure 3C). 239 
Accordingly, DGAT1 depletion but not DGAT2 depletion using siRNA also resulted in a 240 
reduction in phosphorylated S6 and accompanying increase in phosphorylated eEF2 241 
(Figure 3C and Supplementary Figure 3D). Conversely, stable expression of DGAT1 in 242 
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DGAT1low 888MEL melanoma cells (Figure 1D) as well as transient over-expression of 243 
DGAT1 in two other melanoma cell lines resulted in elevated phospho-S6 (Figure 3D 244 
and Supplementary Figure 3E). 245 
Given the effect of DGAT1 antagonism on mTOR signaling, which is heavily 246 
implicated in cell growth and division, we next addressed the importance of DGAT1 for 247 
melanoma cell proliferation. DGAT1 depletion using siRNA reduced cell proliferation 248 
and decreased the fractions of cells in S-phase (Figure 3C and Supplementary Figure 249 
3G), which was in contrast to the increased proliferation and cell cycle progression 250 
observed with stable DGAT1 overexpression (Figure 3D and Supplementary Figure 3F). 251 
To determine whether these effects were due to the enzymatic function of DGAT1 we 252 
utilized four selective DGAT1 inhibitors (AZD3988, AZD7687, A229500 or T863). 253 
Pharmacological antagonism of DGAT1 suppressed melanoma cell growth over 96h 254 
(Figure 4A), accompanied by decreased cell-cycle progression (Figure 4B).   In 255 
contrast, no changes in cell growth or cell cycle progression were observed following 256 
DGAT2 depletion or inhibition (Supplementary Figure 3B, C). Corroborating the link 257 
between DGAT1, S6K activity, and proliferation, over-expression of wild-type p70S6K, 258 
or a constitutively active form, partially restored cellular proliferation and phospho-S6 259 
levels in DGAT1-suppressed melanoma cells (Figure 4C and Supplementary Figure 260 
4D). Conversely, stable expression of DGAT1 in 888MEL melanoma enhanced cell 261 
proliferation and this was reversed by pharmacological antagonism of S6K using 262 
LY2584702 or PF-4708671 (Figure 4E). Taken together, we conclude that DGAT1 263 
promotes melanoma cell proliferation by stimulating S6K activity. 264 
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Cancer cells are capable of sustaining cell growth despite transient or limited 265 
nutrient availability in the tumor microenvironment arising from poor vascularization 266 
(29). Given the connection suggested by gene set enrichment analysis between genes 267 
differentially expressed in Dgat1a over-expressing tumors and HIF1 regulation of 268 
glycolysis (Figure 2H), we investigated the role of DGAT1 in allowing cancer cells to 269 
tolerate nutrient and oxygen deprivation in culture. First, we found that DGAT1 270 
antagonism greatly impaired proliferation when external lipid sources were restricted, 271 
with the greatest reduction in cell number observed at the lowest levels of serum (Figure 272 
4F). The suppressive effect of DGAT1 inhibition on S6K activity was also observed in 273 
lipid-restricted media (Supplementary Figure 4E). Second, we explored the importance 274 
of DGAT1 under hypoxic conditions. Again, we found that DGAT1 inhibition had a 275 
profound effect on cell number under low oxygen conditions, which was further 276 
exacerbated by limiting serum (Figure 4G). Relative to growth of non-transfected cells, 277 
transient DGAT1 overexpression augmented melanoma cell growth to a greater extent 278 
under hypoxic conditions (Supplementary Figure 4F). Taken together up-regulation of 279 
DGAT1 confers a growth advantage to melanoma cells, which is even more profound 280 
under stress conditions likely to be encountered in the tumor microenvironment.  281 
 282 
DGAT1 is essential for lipid droplet formation and acts as a caretaker of 283 
mitochondrial health 284 
The capacity of DGAT1 to sequester FA and DAG in LD has the potential to affect both 285 
cell growth signaling and ATP production, as FA, DAG and their derivatives are 286 
allosteric regulators of various metabolic enzymes, kinases and transcription factors, 287 
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and FA are also fuel molecules. Therefore, to address directly the effect of DGAT1 on 288 
melanoma lipid metabolism using an unbiased approach, we performed Ultra-High-289 
Performance Liquid Chromatography-Mass-Spectrometry (UHPLC-MS) to identify and 290 
contrast lipid species extracted from NRASmut Dgat1a over-expressing or NRASmut 291 
EGFP-expressing zebrafish tumors. This analysis revealed increased concentrations of 292 
almost all TAG species detected in tumors with forced Dgat1a expression, with longer 293 
poly-unsaturated FA (PUFA) chains showing the greatest increases (Figure 5A, 294 
Supplementary Figure 5A and Supplementary Table 3). However, after correction for 295 
multiple testing, the changes were no longer significant. This lack of significance does 296 
not necessarily disprove the hypothesis that DGAT can impact TAG levels, as several 297 
experimental limitations exist that may confound the analysis. First, EGFP-expressing 298 
tumors also over-express Dgat1a and have ample LD (19). Second, lipids originating 299 
from associated stromal cells dilute the lipids derived from tumor cells. Both issues 300 
mean that lipidome differences between Dgat1-over-expressing and EGFP-expressing 301 
tumors are likely to be reduced in magnitude. 302 
In order to overcome the complexity of whole tumor analysis, we turned to 303 
melanoma cell lines. Over-expression of DGAT1 in human melanoma cells resulted in a 304 
striking increase in LD (Figure 5B) consistent with cells adopting an engorged 305 
morphology (Figure 5B). In parallel, UHPLC-MS lipidomic analysis revealed an increase 306 
in almost all TAG species (Figure 5B and Supplementary Table 4, 5), corroborating the 307 
trend in TAG seen in zebrafish tumors over-expressing Dgat1a (Figure 5A). Conversely, 308 
inhibition of DGAT1 in melanoma cell lines over-expressing endogenous DGAT1 led to 309 
a reduction in the amount of LD beginning between 12 and 24h and continuing until 72h 310 
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(Figure 5C and Supplementary Figure 5B, C), as previously reported for other cell types 311 
(30). In contrast, LD were not affected by DGAT2 depletion (Supplementary Figure 5D). 312 
As expected, UHPLC-MS lipidomic analysis revealed a reduction of multiple TAG 313 
species already at 24h that was maintained until 72h, (Figure 5D, Supplementary Figure 314 
5E and Supplementary Table 6, 7), with TAG containing PUFA particularly affected 315 
(Supplementary Figure 5A). 316 
Alongside the anticipated changes in TAG levels following manipulation of 317 
DGAT1 activity, we also observed a decrease in several acyl carnitine (AcCa) species 318 
upon DGAT1 overexpression (Figure 5B and Supplementary Table 4, 5) and a 319 
reciprocal increase in AcCa species following DGAT1 inhibition (Figure 5D, E, 320 
Supplementary Figure 5E and Supplementary Table 6, 7). AcCa, formed by 321 
esterification of FA (typically long-chain) to L-carnitine, are transported into mitochondria 322 
to be processed into acetyl-CoA through β-oxidation. The production of AcCa 323 
determines the rate of FAO (31). PDK3 and PDK4 are mitochondrial kinases that 324 
suppress conversion of pyruvate to acetyl-CoA when alternative fuel sources to 325 
glucose, such as FA, are available (32). The increase in PDK3 and PDK4 activity we 326 
detected following DGAT1 inhibition through our phospho-proteomic analysis (Figure 327 
3A) was therefore consistent with increased AcCa availability and hence increased 328 
FAO. Moreover, excessive FAO can result in mitochondrial overloading and dysfunction 329 
(33). Indeed, we observed evidence of impaired ATP production following DGAT1 330 
inhibition, implied by the increased phosphorylation of both AMPK and RAPTOR (Figure 331 
5F). Further, we observed reduced oxygen consumption in DGAT1 inhibited cells after 332 
48h (Figure 5G), implying decreased mitochondrial respiratory function despite levels of 333 
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AcCa remaining elevated (Figure 5D and Supplementary Figure 5E). Additionally, post 334 
24h DGAT1 inhibition, we observed loss of mitochondrial membrane potential, 335 
decreased PINK1 cleavage, and increased levels of mitophagy factor PARKIN (Figure 336 
5H). Moreover, by blocking AcCa synthesis using Etomoxir (a carnitine 337 
palmitoyltransferase inhibitor), we could partially restore mitochondrial membrane 338 
potential and cell proliferation (Supplementary Figure 5F, G). Thus, we conclude that 339 
DGAT1 maintains mitochondrial function in melanoma cells by regulating availability of 340 
FA for FAO. 341 
 342 
DGAT1 promotes survival of melanoma cells in the presence of ROS 343 
To understand the effects of prolonged DGAT1 inhibition (post 72hr) on cellular 344 
signaling and metabolism we performed unbiased MS-based whole proteome analysis 345 
in SILAC-labelled A375 cells. Analysis of differentially expressed proteins highlighted 346 
three key areas: i) FA oxidation (consistent with increased AcCa availability and PDK 347 
activity), ii) PPAR signaling presumably indicating the increased availability of lipid 348 
regulators of PPAR activity, and iii) NRF2 signaling, which is a well-established 349 
response to ROS production that dampens ROS-mediated cellular damage (34) (Figure 350 
6A, and Supplementary Figure 6A-B). Quantitative gene expression analysis further 351 
corroborated the effects of DGAT1 inhibition on these three key biological processes 352 
(Figure 6B and Supplementary Figure 6C). 353 
To measure the impact of DGAT1 suppression on ROS more directly, we stained 354 
cells with fluorescent probes that are uncaged by ROS. Using this method, we observed 355 
increasing levels of ROS over time upon both DGAT1 inhibition and depletion in multiple 356 
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melanoma cell lines (Figure 6C,D and Supplementary Figure 6D,E), including in the 357 
mitochondria specifically (Supplementary Figure 6F), a predicted consequence of 358 
excessive FAO (33). Through a chain reaction, oxygen-centered ROS can yield highly 359 
reactive cytotoxic lipid species termed lipid peroxides responsible for a form of 360 
programmed cell death termed ferroptosis (35). Accordingly, in parallel with increased 361 
ROS generation, DGAT1 inhibition led to an increase in the peroxidation of lipids from 362 
24h, with further increases by 48h both in the cytoplasm (Figure 6E) and mitochondria 363 
specifically (Figure 6F). Additionally, depletion of DGAT1 resulted in increased protein 364 
attachment of 4-Hydroxynonenal (4HNE) (Figure 6G), a by-product of lipid peroxidation. 365 
Conversely, we observed decreased protein attachment of 4-Hydroxynonenal (4HNE) in 366 
DGAT1 over-expressing melanoma cells (Figure 6H) and also in zebrafish tumors over-367 
expressing Dgat1a (Figure 6I), indicating that lipid peroxidation and its suppression by 368 
DGAT1 occurs not only in cell lines but also within tumors. 369 
We next investigated whether the induction of ROS upon DGAT1 suppression 370 
affected the survival of melanoma cells. In parallel with ROS generation, we observed 371 
induction of ROS response markers, including SOD1 and SOD2 (Figure 7A, 372 
Supplementary Figure 7A), and apoptosis induction in some DGAT1high cell lines after 373 
prolonged DGAT1 suppression (Figure 7A, B and Supplementary Figure 7B); again, an 374 
effect not observed following DGAT2 inhibition (Supplementary Figure 7C, D). 375 
Moreover, ROS scavengers Tempol and Ebselen partially suppressed apoptosis 376 
induced by DGAT1 depletion (Figure 7B). Conversely, stable over-expression of DGAT1 377 
in DGAT1low 888MEL melanoma cells was protective against ROS-mediated cell death 378 
triggered by chemical ROS inducers (Figure 7C). Further underpinning the observation 379 
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that DGAT1 confers a protective effect on melanoma cells in stressful conditions, 380 
DGAT1 over-expression significantly increased cell survival under hypoxic conditions 381 
(even with limited serum). Further, SOD2 induction was tempered by elevated DGAT1 382 
activity, indicating suppression of ROS induction (Figure 7D). Thus, DGAT1 promotes 383 
the survival of melanoma cells by suppressing ROS production and lipid peroxidation 384 
that would otherwise occur as a result of cancer specific altered FA metabolism. 385 
DGAT1 inhibition resulted in apoptosis only in a proportion of cells and in a 386 
variable fraction dependent on cell line suggesting that not all affected cells produce 387 
toxic ROS levels. We therefore hypothesized that anti-ROS mechanisms were activated 388 
in some cells, counteracting the effects of DGAT1 suppression. We wanted to 389 
investigate how the anti-ROS response was being coordinated downstream of DGAT1 390 
inhibition in order to identify targets that might synergize with DGAT1 inhibition. mRNA 391 
for the NRF2 target SESTRIN2 (SESN2) was found to be highly up-regulated post 392 
DGAT1 inhibition (Figure 6B). Accordingly, SESN2 protein was consistently and 393 
significantly up-regulated in a panel of melanoma cell lines following DGAT1 inhibition 394 
(Figure 7E). Intriguingly, SESN2 is a major mediator of NRF2 signaling responsible for 395 
neutralizing ROS while simultaneously inhibiting mTOR signaling (36). This suggests 396 
that SESN2 induction may mediate, but also ameliorate the impact of DGAT1 inhibition 397 
on cell growth and survival. Supporting this hypothesis, simultaneous depletion of 398 
SESN2 and DGAT1 resulted in a greater reduction in surviving cell numbers (Figure 399 
7F), coinciding with increased apoptosis, compared to DGAT1 depletion or inhibition 400 
alone (Figure 7F, Supplementary Figure 7E). Simultaneous knockdown of SESN2 and 401 
inhibition of DGAT1 (Supplementary Figure 7F) also led to both elevated levels of ROS 402 
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(Figure 7G) and increased expression of the NRF2 target gene HMOX1 (Figure 7H) 403 
compared to DGAT1 inhibition alone, indicating that without SESN2 induction the 404 
neutralization of ROS is impaired. Moreover, we found that the reduction of mTOR 405 
signaling induced by DGAT1 inhibition was alleviated by knockdown of SESN2 406 
(Supplementary Figure 7G). Thus, SESN2 acts as a counterfoil to DGAT1, suppressing 407 
mTOR signaling while ameliorating ROS inflicted damage. 408 
 409 
DISCUSSION  410 
The role of dysregulated lipid metabolism, encompassing more than just de novo FA 411 
synthesis, in promoting neoplasia is increasingly apparent (8,9,12,37). However, the 412 
adaptations allowing cancer cells to tolerate exposure to excess FA have been 413 
overlooked. Using multiple zebrafish models, integrating outputs across multiple omics 414 
platforms, including oncogenomic, transcriptomic, proteomic, phospho-proteomic, and 415 
lipidomic, combined with assays of cell behavior, we now demonstrate that DGAT1 is a 416 
novel bona fide metabolism oncoprotein that stimulates melanoma tumorigenesis. We 417 
conclude that DGAT1 promotes proliferation through mTOR–S6K signaling. We also 418 
show that DGAT1 promotes survival principally by conferring protection against ROS 419 
and lipid peroxidation through inducing LD formation (see model; Supplementary Figure 420 
7H). 421 
We uncovered frequent amplification and up-regulation of DGAT1 in melanoma 422 
but also in many other cancers, notably ovarian, breast, uterine, esophageal, liver, 423 
pancreatic, head and neck, prostate, stomach and lung cancers. Abundant LD have 424 
been observed in a range of cancers, consistent with widespread up-regulation of 425 
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DGAT1 (38,39), indicating that DGAT1 is likely to perform an oncogenic role in these 426 
other cancers too. The co-occurrence of DGAT1 amplification with FASN, CD36, or 427 
MAGL amplification in human cancers was significant (data not shown), arguing for 428 
these co-aberrations being synergistic, in keeping with DGAT1 facilitating safe 429 
accumulation of FA in cancer cells.  430 
Multiple indirect mechanisms connect DGAT1 enzymatic activity with S6K 431 
activity. On the one hand, by promoting mitochondrial respiratory function and ATP 432 
generation, DGAT1 suppresses AMPK thereby relieving inhibition of mTOR (40). 433 
Further, through curbing ROS generation by malfunctioning mitochondria, DGAT1 434 
activity represses NRF2 activation and induction of SESN2, a known inhibitor of mTOR 435 
(36). Accordingly, knockdown of SESN2 rescued the S6K suppression ensuing DGAT1 436 
inhibition. Other potential DGAT1-dependent factors that could impact mTOR signaling 437 
include phosphatidic acid, essential for mTOR activity (41), and DAG, which co-activate 438 
PKC that in turn inhibit growth factor signaling to mTOR (42). Levels of these lipids 439 
could be rapidly affected by DGAT1-driven sequestration of DAG and FA as TAG in LD. 440 
However, changes in concentration of these lipid species following manipulation of 441 
DGAT1 activity or expression were not readily apparent from our lipidomics analyses, 442 
perhaps limited by their low abundance, instability, rapid association with proteins in the 443 
cell, or a combination of all the above. Intriguingly, mTOR–S6K signaling has been 444 
shown to induce lipogenesis and LD formation (37,43,44), suggesting that mTOR 445 
signaling and lipogenesis are mutually re-enforcing events. 446 
We propose that sequestration of FA as TAG in LD allows cancer cells to 447 
accumulate and utilize FA safely, thereby avoiding cell death. As previously described in 448 
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non-transformed embryonic fibroblasts (30), we observed that DGAT1 suppression 449 
resulted in overloading of mitochondria with AcCa, driving excessive FAO and ROS 450 
production. Thus, the pathophysiological role of DGAT1 is to regulate the supply of FA 451 
to mitochondria within safe limits. Evidently, cancer cells, having elevated FA, require 452 
more DGAT1 to achieve this. Lipid peroxides are especially cytotoxic and are generated 453 
by the action of oxygen-centered radicals on polyunsaturated fatty acids (PUFA) 454 
preferentially (45). As PUFA are concentrated in LD where they are shielded from 455 
peroxidation (46), enhanced LD levels mediated by DGAT1 up-regulation confer double 456 
protection from cell death by both moderating FAO-triggered ROS production and 457 
simultaneously shielding them from PUFA peroxidation.  458 
LD are known to protect non-transformed and transformed cells against a range 459 
of cellular stresses typically encountered in the tumor microenvironment, including 460 
nutrient deprivation and hypoxia (38,39). Indeed, these conditions induce LD formation 461 
downstream of autophagy (30). Additionally, low pH up-regulates DGAT1 and 462 
consequently increases LD formation. In turn, LD were required for acidosis-induced 463 
metastasis (47). Nutrient deprivation and hypoxia compromise de novo FA synthesis 464 
and desaturation. Unsaturated FA are essential for membrane fluidity and cell viability, 465 
and in the absence of desaturation reactions, or the ability to scavenge unsaturated FA 466 
from the circulation, cancer cells must draw on LD for unsaturated FA in order to survive 467 
(48). The above role for LD is consistent with our observation that the effect of DGAT1 468 
suppression on cell number was exacerbated by serum withdrawal and hypoxia and 469 
explains why conversely DGAT1 overexpression conferred its greatest growth 470 
advantage under these conditions. 471 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 24, 2020. . https://doi.org/10.1101/2020.06.23.166603doi: bioRxiv preprint 
 21 
Our data indicate that DGAT1 inhibition alone could be therapeutic in tumors 472 
addicted to DGAT1, although diarrhea attendant on blocking fat absorption through the 473 
gut (49) would have to be managed in patients. The identification of signaling molecules 474 
such as SESN2, whose suppression synergized with DGAT1 antagonism to produce 475 
high levels of ROS and significantly elevated cell death, might one-day feed into a 476 
strategy that allows DGAT1 inhibitor concentration to be reduced to a well-tolerated 477 
dose. Moreover, such pro-oxidant therapies could inhibit the progression of melanoma, 478 
as oxidative stress limits melanoma metastasis (50).  479 
Up-regulation of DGAT1 likely has additional profound consequences for cancer 480 
progression, perhaps explaining the association between DGAT1 amplification and 481 
progression-free survival that we uncovered. Enhanced FA uptake and FAO are 482 
particularly prominent in tumor initiating cells (9) and DGAT1 could play a critically 483 
important role in this crucial subset of tumor cells. It was recently shown that FAO 484 
activity correlates with antigen presentation in melanoma and responsiveness to 485 
immune checkpoint immunotherapy (51). In fatty liver disease, lipid peroxide adducts 486 
were shown to be highly immunogenic and drive adaptive immune responses (52). We 487 
found that both substrate production for FAO and lipid peroxidation were suppressed by 488 
DGAT1 up-regulation. Moreover, it has been found that LD are enriched with COX2 and 489 
arachidonic acid and are major sites of PGE2 synthesis (53). PGE2 has wide ranging 490 
suppressive effects on cellular immunity (54). Thus, DGAT1 up-regulation could 491 
promote immune evasion by tumor cells and potentially diminish immunotherapy 492 
responses; DGAT1 inhibitors might therefore synergize with immunotherapy.  493 
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Overall, our findings demonstrate that overexpression of the oncoprotein DGAT1, 494 
with or without gene amplification, is a beneficial adaptation of cancer cells. DGAT1 495 
overexpression permits accumulation of fatty acids, useful as an energy source, for 496 
lipogenesis and for signal transduction, while avoiding suppression of growth factor 497 
signaling and induction of oxidative stress. 498 
 499 
ACKNOWLEDGEMENTS  500 
We thank David Knight and the staff of the Biological Mass Spectrometry (BioMS) 501 
facility, Michael Jackson in the FACs facility, staff of the Bio-imaging facility, The 502 
Genomic Technologies Core Facility (GTCF) (all FBMH, UoM) for experimental support. 503 
We thank Olivia Sloss and Angeliki Malliri for critically reading the manuscript. AH was 504 
funded by grant ERC-2011-StG-282059 from the ERC, grant 610262 from the 505 
Melanoma Research Alliance, and a PhD studentship A23251 from Cancer Research 506 
UK to support DJW. CF was supported by the Wellcome Trust (Sir Henry Dale 507 
fellowship grant number 107636/Z/15/Z) and Biotechnology and Biological Sciences 508 
Research Council (grant number BB/R015864/1). The Medical Research Council (MRC) 509 
funded the Phenome Centre Birmingham (MR/M009157/1).  510 
 511 
Author Contributions: Cell line-based experimentation: DJW, MPS, RO, JH. Zebrafish 512 
models: APB, DJW, HJ, MG, CC. Proteomics: MPS, DJW, PF, CF. Lipidomics: DJW, 513 
MPS, ADS, DR, AJ, GRL, WBD. Bio-informatics analysis: DJW, SO, JW, HF, CF, ADS, 514 
AJ, GRL, DR, WBD, MPS. Experimental design: DJW, APB, CF, MPS, AH. Sample 515 
acquisition and cell lines: PL, CW, MPS, AH. Conceptualization: APB, MPS, AH. 516 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 24, 2020. . https://doi.org/10.1101/2020.06.23.166603doi: bioRxiv preprint 
 23 
Drafting manuscript: DJW, APB, MPS, AH. Revisions by all authors. Acquisition of 517 
funds: CW, CF, AH. Study supervision MPS, AH.  518 
 519 
Competing interest: No competing interests to declare. 520 
 521 
Supplementary Materials contains supplemental methods, figures and tables.  522 
 523 
Methods  524 
Zebrafish models 525 
Regulated procedures involving zebrafish were ethically approved by The University of 526 
Manchester Animal Welfare and Ethical Review Body (AWERB), or by the UMMS 527 
Institution Animal Care and Use Committee (A-2016, A-2171), and carried out under a 528 
licence issued by the appropriate national regulatory authority. Zebrafish were housed 529 
at ~28 °C under a 14 h light/10 h dark cycle. Transgenic zebrafish expressing 530 
BRAFV600E or NRASG12D have been previously described (28,55) and were crossed onto 531 
a mitfaw2/w2 (mitfa-/-) background to suppress melanocyte development and further onto 532 
a tp53M214K/M214K background to promote tumorigenesis. Melanocyte restoration and 533 
simultaneous over-expression of Dgat1a, Dgat2 or EGFP was then achieved by 534 
injection of embryos with a mitfa-minigene containing plasmid as previously described 535 
(28). Briefly, zebrafish dgat1a and dgat2 were amplified from cDNA of wild-type 48 h 536 
post-fertilisation zebrafish embryos, and subcloned into the pDONR221 vector (see 537 
Supplementary Table 8 for oligonucleotide sequences). The pDest-mitfa:dgat1a-pA and 538 
pDest-mitfa:dgat2-pA destination vectors were created using an LR clonase reaction 539 
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consisting of p5E-mitfap, pME-dgat1a or pME-dgat2, p3E-pA and an empty destination 540 
vector. Expression plasmid was injected into zebrafish zygotes along with Tol2 mRNA. 541 
pCS2-TP plasmid for Tol2 mRNA generation was a kind gift from Dr Koichi Kawakami 542 
(National Institute of Genetics). Sufficient embryos for all experimental arms were 543 
generated simultaneously, pooled and then randomly assigned to a construct, although 544 
formal randomization techniques were not used. Zebrafish were group-housed 545 
according to the construct. Only zebrafish embryos with near complete melanocyte 546 
rescue at 5 days were retained for further analysis. Analysis of tumor formation was not 547 
performed blinded to the construct identity. Sample sizes were not predetermined based 548 
on statistical power calculations but were based on our experience with these assays. 549 
To assess the statistical significance of differences in overall survival, we used Mantel–550 
Cox’s log-rank tests. 551 
 552 
Cell Lines  553 
Human melanoma cell lines were cultured in High Glucose DMEM with 10 % FBS, and 554 
penicillin–streptomycin (Sigma) at 37  °C and 5 % CO2. Normal human melanocytes 555 
were purchased from Cascade Biologics and cultured according to manufacturer´s 556 
guidelines. Lenti-X cells were cultured in High Glucose DMEM with 10 %v/v FBS, and 557 
penicillin–streptomycin (Sigma) at 37  °C and 5 % CO2. All cells tested negative for 558 
mycoplasma and cell lines were authenticated using STR profiling. 559 
Cell line Genetic drivers DGAT1 status 
888MEL BRAFV600E DGAT1 low 
SKMEL28 BRAFV600E DGAT1 medium 
SKMEL2 NRASQ61R DGAT1 over expressed  
MM485 NRASQ61R DGAT1 over expressed 
A375 BRAFV600E DGAT1 over expressed 
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SKMEL105 BRAFV600E DGAT1 over expressed 
LOXIMVI BRAFV600E DGAT1 amplified 
SKMEL5 BRAFV600E DGAT1 amplified 
 560 
Compounds and Antibodies  561 
Compounds were used at the following concentrations unless otherwise noted 50 μM 562 
AZD3988 (Tocris), 30 μM A922500 (Stratech) 50 μM AZD7687, 70 μM T863 (Sigma), 1 563 
μM Oligomycin (Sigma), 0.5 μM FCCP (Sigma), 1 μM Antimycin-A (Sigma), 1 μM 564 
Rotenone (Sigma), 50 μM PF-06424439 (Sigma), 5 μM Ebselen (Tocris), 1 mM Tempol, 565 
200 μM Paraquat (Sigma), Menadione (Sigma), 100 μM Etomoxir (Sigma), 1 μM 566 
LY2584702 (Stratech), 10 μM PF-4708671 (Generon). 567 
Antibodies against DGAT1 (ab54037), phospho-PDE1a (ab92696) and 4-568 
Hydroxynonenal (ab46545) were purchased from abcam. Antibodies against Vinculin 569 
(66305-1-Ig), Beta-Tubulin (10094-1-AP), PINK1 (23274-1-AP), Parkin (14060-1-AP), 570 
SOD1 (10269-1-AP), SOD2 (24127-1-AP), Sestrin 2 (10795-1-AP), GAPDH (60004-1-571 
Ig), and PDK4 (12949-1-AP) were purchased from Proteintech. Antibodies against 572 
phospho-S6 (2215), phospo-eEF2 (2331), phospho-AMPK (50081), phospho-RAPTOR 573 
(2083), Caspase-3 (9662), phospho-P70 S6 kinase (9206), P70 S6 Kinase (2708), S6 574 
(2317) and GFP (2956) were purchased from Cell Signalling. The Antibody against HA 575 
(901533) was purchased from Biolegend. The Antibody against gamma-tubulin (T5326) 576 
was purchased from Sigma. 577 
 578 
Plasmids & siRNA 579 
All plasmids were transfected using Lipofectamine (Invitrogen) following standard 580 
protocols. The plasmids used were purchased from Addgene: pRK7-HA-S6K1-WT 581 
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(8984); pRK7-HA-S6K1-F5A-E389-deltaCT (8990); pcDNA3.1-mMaroon1 (83840). The 582 
GFP and WPRE elements were excised from pCDH-MCS-T2A-copGFP (a kind gift from 583 
Andrew Gilmore, The University of Manchester) using BspEI and KpnI. mApple (BspEI 584 
and XhoI adapters) and WPRE (XhoI-KpnI adapters) were PCR amplified, digested and 585 
subcloned to create the pCDH-MCS-T2A-mApple vector (see Supplementary Table 8 586 
for oligonucleotide sequences). DGAT1 was further subcloned into the both the 587 
pCDNA3.1 vector and pCDH-MCS-T2A-mApple using the MCS. 588 
All siRNA was transfected using Lipofectamine RNAi Max (Invitrogen) following 589 
standard protocols. The following siRNA were ordered from Dharmacon: DGAT1 007 5’ 590 
UCAAGGACAUGGACUACUC 3’; DGAT1 008 5’ GCUGUGGUCUUACUGGUUG 3’; 591 
DGAT1 smart pool #J-009333-00-0005; DGAT2 01 5’ GAACACACCCAAGAAAGGU 3’; 592 
DGAT2 02 5’GGAGGUAUCUGCCCUGUCA3’; DGAT2 03 5’ 593 
UCAUGGAGCUGACCUGGUU 3’; DGAT2 04 5’GAAUGCCUGUGUUGAGGGA 3’; 594 
DGAT2 smart pool #J-009333-08; SESN2 19 5’GGAGGGAGUAUUAGAUUAU3’; 595 
SESN2 20 5’GCAGGGACCCGUUGAACAA3’.  The scrambled control siRNA (SIC002) 596 
was ordered from Sigma. 597 
 598 
Viral transduction  599 
Briefly, Lenti-X cells were transfected with pMDLg/pRRE, pMD2.G, pRSV-Rev plasmids 600 
(all kind gifts from Angeliki Malliri, Cancer Research UK Manchester Institute) and 601 
pCDH-EF1α-DGAT1-T2A-mApple viral vectors using Fugene (Promega) following 602 
standard protocols. The viral containing supernatant was filtered using a 0.45 μm filter 603 
and frozen at –80 °C prior to transduction of target cells. The supernatant containing the 604 
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viral particles was added to target cells along with 10 ng/ml Polybrene (Millipore) for 24 605 
h. Target cells were then grown and selected from single cell colonies. 606 
 607 
Protein lysate preparation and Western Blotting  608 
Cells were washed with PBS and lysed with sample buffer (62.5 mM TRIS pH 6.8, 2 609 
%w/v Sodium dodecyl sulfate (SDS), 10 %v/v glycerol, 0.01%w/v bromophenol blue, 3 610 
%v/v 2-mercaptoethanol). Lysates were then sonicated and heated to 95°C for 10 611 
minutes prior to being evenly loaded onto SDS-polyacrylamide gels using the Mini 612 
Trans-Bot electrophoresis system (Biorad), followed by transfer to PVDF using standard 613 
western blotting procedures.  614 
 615 
Lipid droplet staining and image analysis 616 
Bodipy 493/503 617 
Indicated cells were stained with 2 μM Bodipy 493/503 (ThermoFisher Scientific) and 5 618 
ng/ml Hoecsht 3342 (Cell Signalling) for 30 minutes prior to fixing in 4 %w/v 619 
paraformaldehyde and imaging using a Leica microscope system. Images were 620 
processing using Fiji. 621 
Lipidtox  622 
Indicated cells were fixed in 4 %w/v paraformaldehyde and stained with LipidTox Green 623 
(ThermoFisher Scientific) according to manufacturer's instructions, and 5ng/ml Hoecsht 624 
3342 (Cell Signalling) for 15 minutes prior to imaging using a Leica microscope system. 625 
Images were processing using Fiji. 626 
 627 
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RNA Isolation and real-time PCR analysis  628 
RNA from cell lines was isolated with TRIZOL® (Invitrogen). After chloroform extraction 629 
and centrifugation, 5 µg RNA was DNase treated using RNase-Free DNase Set 630 
(Qiagen). 1 µg of DNase treated RNA was then taken for cDNA synthesis using the 631 
Protoscript I first strand cDNA synthesis kit (New England Biolabs). Selected genes 632 
were amplified by quantitative real time PCR (RT-qPCR) using Sygreen (PCR 633 
Biosystems). Relative expression was calculated using the delta-delta CT methodology 634 
and beta-actin was used as reference housekeeping gene. Sequences for primers used 635 
can be found in the Supplementary Table 8. 636 
 637 
Incucyte cell-proliferation assay and apoptosis assay 638 
Indicated cell lines were seeded into 24-well plates at a density of 15,000–20,000 cells 639 
per well, depending on growth rate and the design of the experiment. After 24 h drugs 640 
or siRNA were added and cells were imaged every hour using the Incucyte ZOOM 641 
(Essen Bioscience) Phase-contrast images were analysed to detect cell proliferation 642 
based on cell confluence. For cell apoptosis, caspase-3 and caspase-7 green 643 
apoptosis-assay reagent (Life Technologies) was added to the culture medium following 644 
manufacturer’s instructions. Cell apoptosis was analysed based on green fluorescent 645 
staining of apoptotic cells. 646 
 647 
Flow cytometry  648 
Mitochondrial Membrane potential  649 
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Indicated cell lines were trypzinized and pelleted by centrifugation at 500 g for 5 min, 650 
washed with PBS. For mitochondrial membrane potential cells were stained with 2 μM 651 
JC-1 (Life Technologies) for 30 minutes at 37 °C. For positive control samples 0.5µM 652 
FCCP was added simultaneously with JC-1. Data was acquired by the BD BIOsciences 653 
Foretessa and quantified using the Flowjo software. A minimum of 10,000 cells were 654 
analysed per condition. 655 
 656 
Lipid peroxidation  657 
Indicated cell lines were trypzinized and pelleted by centrifugation at 500 g for 5 min, 658 
followed by a PBS wash. For lipid peroxidation cells were stained with either 5 μM 659 
BODIPY™ 581/591 C11 (ThermoFisher Scientific) or MitoPerOx (Abcam) for 30 660 
minutes at 37 °C. Data was acquired by the BD BIOsciences Foretessa and quantified 661 
using the Flowjo software. A minimum of 10,000 cells were analysed per condition. 662 
 663 
Mitochondrial ROS 664 
Indicated cell lines were trypzinized and pelleted by centrifugation at 500 g for 5 min, 665 
followed by a PBS wash. For mitochondrial specific ROS detection, cells were stained 666 
with 2.5 μM Mitosox (ThermoFisher Scientific) for 30 minutes at 37 °C. Data was 667 
acquired by the BD BIOsciences Foretessa and quantified using the Flowjo software. A 668 
minimum of 10,000 cells were analysed per condition. 669 
 670 
Proliferation Assays  671 
Crystal Violet  672 
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Indicated cells were stained and fixed with 0.5 %w/v crystal violet (Sigma) in 4 %w/v 673 
paraformaldehyde/PBS for 30 minutes. Fixed cells were then solubilised in 2 %w/v 674 
SDS/PBS and absorbance measured at 595 nm using Synergy H1 microplate reader 675 
(BioTek). 676 
EdU Incorporation 677 
Indicated cells were labelled with 20 µM 5-ethynyl-2'-deoxyuridine (EdU) for 4 h and 678 
processed following the manufacturer's protocol (Click-iT® EdU Alexa Fluor® 488 679 
Imaging Kit, Thermo Fisher). Prior to imaging cells were then stained with 5ng/ml 680 
Hoecsht 3342 for 15 minutes. Stained cells were analysed using a using a Leica 681 
microscope system. Images were processing using Fiji. 682 
 683 
Dihydroethidium Assay 684 
Cells were stained with 5 μM Dihydroethidium for 20 minutes in the dark at 37 °C. 685 
Fluorescence was measured at excitation 480nm emission 570 nm using Synergy H1 686 
micro plate reader (BioTek). Fluorescence values were normalised to cell number by 687 
staining the cells with crystal violet after fluorescence read. 688 
 689 
Cancer bioinformatics 690 
We evaluated both point mutations and CNV in the TCGA SKCM firehose legacy, 691 
TCGA pan-cancer and Cancer Cell Line Encyclopedia datasets using the cBioPortal 692 
platform (56). The GISTIC2.0 algorithm was used to identify focal amplifications (57). 693 
Gene Ontology analysis was carried out using both enrichR (58) and metascape 694 
software (59). Association between mRNA expression in TCGA datasets and survival 695 
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was evaluated using OncoLnc (60). mRNA levels determined by microarray were 696 
accessed through the Oncomine platform (61). 697 
 698 
Quantification and Statistical Analysis  699 
Data was tested for normality using the Shapiro-Wilk test. Data was considered to be 700 
normally distributed if p>0.05. Differences in the number of lipid droplets per cell, 701 
relative cell number and percentage EdU incorporation between DMSO and drug 702 
treated cells were assessed using an unpaired two-sided t-test, or Mann-Whitney test if 703 
data were not normally distributed. In comparing the differences in these same 704 
characteristics between cells transfected with either non-target or one of several siRNA 705 
oligonucleotides, a one-way ANOVA with Tukey’s multiple comparisons test (or 706 
Friedman with Dunn’s multiple comparisons test if data were not normally distributed) 707 
was used to measure significance. Differences were considered significant if p<0.05. All 708 
data obtained was analysed using Graphpad Prism 8.1.  709 
 710 
Data and Code Availability 711 
The zebrafish tumor RNA-seq data has been deposited with the Gene Expression 712 
Omnibus (GEO) with the accession code GSE144555. The mass spectrometry 713 
proteomics data have been deposited with the ProteomeXchange Consortium via the 714 
PRIDE partner repository with the dataset identifier PXD017487. Extended Lipidomics 715 
Data for zebrafish tumors and human melanoma cell lines can be found in 716 
Supplementary Tables 3-7. Code for proteomic analysis can be found at 717 
https://github.com/JoWatson2011/DGAT_2019.  718 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a




1. DeBerardinis RJ, Chandel NS. Fundamentals of cancer metabolism. Sci Adv 721 
2016;2:e1600200-e 722 
2. Andrejeva G, Rathmell JC. Similarities and Distinctions of Cancer and Immune 723 
Metabolism in Inflammation and Tumors. Cell Metabolism 2017;26:49-70 724 
3. Lee SY, Ju MK, Jeon HM, Lee YJ, Kim CH, Park HG, et al. Oncogenic 725 
Metabolism Acts as a Prerequisite Step for Induction of Cancer Metastasis and 726 
Cancer Stem Cell Phenotype. Oxid Med Cell Longev 2018;2018:1027453- 727 
4. Lyssiotis CA, Kimmelman AC. Metabolic Interactions in the Tumor 728 
Microenvironment. Trends Cell Biol 2017;27:863-75 729 
5. Koundouros N, Poulogiannis G. Reprogramming of fatty acid metabolism in 730 
cancer. British Journal of Cancer 2020;122:4-22 731 
6. Chen M, Huang J. The expanded role of fatty acid metabolism in cancer: new 732 
aspects and targets. Precis Clin Med 2019;2:183-91 733 
7. Lengyel E, Makowski L, DiGiovanni J, Kolonin MG. Cancer as a Matter of Fat: 734 
The Crosstalk between Adipose Tissue and Tumors. Trends Cancer 2018;4:374-735 
84 736 
8. Watt MJ, Clark AK, Selth LA, Haynes VR, Lister N, Rebello R, et al. Suppressing 737 
fatty acid uptake has therapeutic effects in preclinical models of prostate cancer. 738 
Science Translational Medicine 2019;11:eaau5758 739 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 24, 2020. . https://doi.org/10.1101/2020.06.23.166603doi: bioRxiv preprint 
 33 
9. Pascual G, Avgustinova A, Mejetta S, Martin M, Castellanos A, Attolini CS, et al. 740 
Targeting metastasis-initiating cells through the fatty acid receptor CD36. Nature 741 
2017;541:41-5 742 
10. Nieman KM, Kenny HA, Penicka CV, Ladanyi A, Buell-Gutbrod R, Zillhardt MR, 743 
et al. Adipocytes promote ovarian cancer metastasis and provide energy for rapid 744 
tumor growth. Nature Medicine 2011;17:1498-503 745 
11. Maan M, Peters JM, Dutta M, Patterson AD. Lipid metabolism and lipophagy in 746 
cancer. Biochemical and Biophysical Research Communications 2018;504:582-9 747 
12. Nomura DK, Long JZ, Niessen S, Hoover HS, Ng S-W, Cravatt BF. 748 
Monoacylglycerol Lipase Regulates a Fatty Acid Network that Promotes Cancer 749 
Pathogenesis. Cell 2010;140:49-61 750 
13. Brookheart RT, Michel CI, Schaffer JE. As a matter of fat. Cell metabolism 751 
2009;10:9-12 752 
14. Molenaar RJ, Maciejewski JP, Wilmink JW, van Noorden CJF. Wild-type and 753 
mutated IDH1/2 enzymes and therapy responses. Oncogene 2018;37:1949-60 754 
15. Flavin R, Peluso S, Nguyen PL, Loda M. Fatty acid synthase as a potential 755 
therapeutic target in cancer. Future Oncol 2010;6:551-62 756 
16. Martín-Martín N, Carracedo A, Torrano V. Metabolism and Transcription in 757 
Cancer: Merging Two Classic Tales. Front Cell Dev Biol 2018;5:119- 758 
17. Rodríguez-Enríquez S, Marín-Hernández Á, Gallardo-Pérez CJ, Pacheco-759 
Velázquez CS, Belmont-Díaz AJ, Robledo-Cadena XD, et al. Transcriptional 760 
Regulation of Energy Metabolism in Cancer Cells. Cells 2019;8 761 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 24, 2020. . https://doi.org/10.1101/2020.06.23.166603doi: bioRxiv preprint 
 34 
18. van Rooijen E, Fazio M, Zon LI. From fish bowl to bedside: The power of 762 
zebrafish to unravel melanoma pathogenesis and discover new therapeutics. 763 
Pigment Cell & Melanoma Research 2017;30:402-12 764 
19. Henderson F, Johnston HR, Badrock AP, Jones EA, Forster D, Nagaraju RT, et 765 
al. Enhanced Fatty Acid Scavenging and Glycerophospholipid Metabolism 766 
Accompany Melanocyte Neoplasia Progression in Zebrafish. Cancer Res 767 
2019;79:2136-51 768 
20. Wilfling F, Wang H, Haas JT, Krahmer N, Gould TJ, Uchida A, et al. 769 
Triacylglycerol synthesis enzymes mediate lipid droplet growth by relocalizing 770 
from the ER to lipid droplets. Dev Cell 2013;24:384-99 771 
21. DeVita RJ, Pinto S. Current Status of the Research and Development of 772 
Diacylglycerol O-Acyltransferase 1 (DGAT1) Inhibitors. Journal of Medicinal 773 
Chemistry 2013;56:9820-5 774 
22. Zhang M, Di Martino JS, Bowman RL, Campbell NR, Baksh SC, Simon-Vermot 775 
T, et al. Adipocyte-Derived Lipids Mediate Melanoma Progression via FATP 776 
Proteins. Cancer Discov 2018;8:1006-25 777 
23. Fischer GM, Vashisht Gopal YN, McQuade JL, Peng W, DeBerardinis RJ, Davies 778 
MA. Metabolic strategies of melanoma cells: Mechanisms, interactions with the 779 
tumor microenvironment, and therapeutic implications. Pigment Cell Melanoma 780 
Res 2018;31:11-30 781 
24. Venkatesan AM, Vyas R, Gramann AK, Dresser K, Gujja S, Bhatnagar S, et al. 782 
Ligand-activated BMP signaling inhibits cell differentiation and death to promote 783 
melanoma. J Clin Invest 2018;128:294-308 784 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 24, 2020. . https://doi.org/10.1101/2020.06.23.166603doi: bioRxiv preprint 
 35 
25. Schlagbauer-Wadl H, Griffioen M, van Elsas A, Schrier PI, Pustelnik T, Eichler 785 
HG, et al. Influence of increased c-Myc expression on the growth characteristics 786 
of human melanoma. J Invest Dermatol 1999;112:332-6 787 
26. Ehlers JP, Worley L, Onken MD, Harbour JW. DDEF1 is located in an amplified 788 
region of chromosome 8q and is overexpressed in uveal melanoma. Clin Cancer 789 
Res 2005;11:3609-13 790 
27. Bastian BC, LeBoit PE, Hamm H, Brocker EB, Pinkel D. Chromosomal gains and 791 
losses in primary cutaneous melanomas detected by comparative genomic 792 
hybridization. Cancer Res 1998;58:2170-5 793 
28. Ceol CJ, Houvras Y, Jane-Valbuena J, Bilodeau S, Orlando DA, Battisti V, et al. 794 
The histone methyltransferase SETDB1 is recurrently amplified in melanoma and 795 
accelerates its onset. Nature 2011;471:513-7 796 
29. Ackerman D, Simon MC. Hypoxia, lipids, and cancer: surviving the harsh tumor 797 
microenvironment. Trends in Cell Biology 2014;24:472-8 798 
30. Nguyen TB, Louie SM, Daniele JR, Tran Q, Dillin A, Zoncu R, et al. DGAT1-799 
Dependent Lipid Droplet Biogenesis Protects Mitochondrial Function during 800 
Starvation-Induced Autophagy. Dev Cell 2017;42:9-21 e5 801 
31. Falomir-Lockhart LJ, Cavazzutti GF, Giménez E, Toscani AM. Fatty Acid 802 
Signaling Mechanisms in Neural Cells: Fatty Acid Receptors. Frontiers in Cellular 803 
Neuroscience 2019;13 804 
32. Zhang S, Hulver MW, McMillan RP, Cline MA, Gilbert ER. The pivotal role of 805 
pyruvate dehydrogenase kinases in metabolic flexibility. Nutrition & Metabolism 806 
2014;11:10 807 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 24, 2020. . https://doi.org/10.1101/2020.06.23.166603doi: bioRxiv preprint 
 36 
33. Koves TR, Ussher JR, Noland RC, Slentz D, Mosedale M, Ilkayeva O, et al. 808 
Mitochondrial Overload and Incomplete Fatty Acid Oxidation Contribute to 809 
Skeletal Muscle Insulin Resistance. Cell Metabolism 2008;7:45-56 810 
34. Sajadimajd S, Khazaei M. Oxidative Stress and Cancer: The Role of Nrf2. Curr 811 
Cancer Drug Targets 2018;18:538-57 812 
35. Conrad M, Pratt DA. The chemical basis of ferroptosis. Nat Chem Biol 813 
2019;15:1137-47 814 
36. Pasha M, Eid AH, Eid AA, Gorin Y, Munusamy S. Sestrin2 as a Novel Biomarker 815 
and Therapeutic Target for Various Diseases. Oxid Med Cell Longev 816 
2017;2017:3296294- 817 
37. Guri Y, Colombi M, Dazert E, Hindupur SK, Roszik J, Moes S, et al. mTORC2 818 
Promotes Tumorigenesis via Lipid Synthesis. Cancer Cell 2017;32:807-23.e12 819 
38. Cruz ALS, Barreto EdA, Fazolini NPB, Viola JPB, Bozza PT. Lipid droplets: 820 
platforms with multiple functions in cancer hallmarks. Cell Death & Disease 821 
2020;11:105 822 
39. Petan T, Jarc E, Jusović M. Lipid Droplets in Cancer: Guardians of Fat in a 823 
Stressful World. Molecules 2018;23 824 
40. Saxton RA, Sabatini DM. mTOR Signaling in Growth, Metabolism, and Disease. 825 
Cell 2017;168:960-76 826 
41. Foster DA. Phosphatidic acid and lipid-sensing by mTOR. Trends Endocrinol 827 
Metab 2013;24:272-8 828 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 24, 2020. . https://doi.org/10.1101/2020.06.23.166603doi: bioRxiv preprint 
 37 
42. Schmitz-Peiffer C, Biden TJ. Protein kinase C function in muscle, liver, and beta-829 
cells and its therapeutic implications for type 2 diabetes. Diabetes 2008;57:1774-830 
83 831 
43. Porstmann T, Santos CR, Griffiths B, Cully M, Wu M, Leevers S, et al. SREBP 832 
Activity Is Regulated by mTORC1 and Contributes to Akt-Dependent Cell 833 
Growth. Cell Metabolism 2008;8:224-36 834 
44. Lee G, Zheng Y, Cho S, Jang C, England C, Dempsey JM, et al. Post-835 
transcriptional Regulation of De Novo Lipogenesis by mTORC1-S6K1-SRPK2 836 
Signaling. Cell 2017;171:1545-58.e18 837 
45. Gaschler MM, Stockwell BR. Lipid peroxidation in cell death. Biochemical and 838 
biophysical research communications 2017;482:419-25 839 
46. Jarc E, Kump A, Malavašič P, Eichmann TO, Zimmermann R, Petan T. Lipid 840 
droplets induced by secreted phospholipase A2 and unsaturated fatty acids 841 
protect breast cancer cells from nutrient and lipotoxic stress. Biochimica et 842 
Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 2018;1863:247-65 843 
47. Corbet C, Bastien E, Santiago de Jesus JP, Dierge E, Martherus R, Vander 844 
Linden C, et al. TGFbeta2-induced formation of lipid droplets supports acidosis-845 
driven EMT and the metastatic spreading of cancer cells. Nat Commun 846 
2020;11:454 847 
48. Ackerman D, Tumanov S, Qiu B, Michalopoulou E, Spata M, Azzam A, et al. 848 
Triglycerides Promote Lipid Homeostasis during Hypoxic Stress by Balancing 849 
Fatty Acid Saturation. Cell Rep 2018;24:2596-605.e5 850 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 24, 2020. . https://doi.org/10.1101/2020.06.23.166603doi: bioRxiv preprint 
 38 
49. Denison H, Nilsson C, Lofgren L, Himmelmann A, Martensson G, Knutsson M, et 851 
al. Diacylglycerol acyltransferase 1 inhibition with AZD7687 alters lipid handling 852 
and hormone secretion in the gut with intolerable side effects: a randomized 853 
clinical trial. Diabetes Obes Metab 2014;16:334-43 854 
50. Piskounova E, Agathocleous M, Murphy MM, Hu Z, Huddlestun SE, Zhao Z, et 855 
al. Oxidative stress inhibits distant metastasis by human melanoma cells. Nature 856 
2015;527:186-91 857 
51. Harel M, Ortenberg R, Varanasi SK, Mangalhara KC, Mardamshina M, Markovits 858 
E, et al. Proteomics of Melanoma Response to Immunotherapy Reveals 859 
Mitochondrial Dependence. Cell 2019;179:236-50 e18 860 
52. Sutti S, Jindal A, Locatelli I, Vacchiano M, Gigliotti L, Bozzola C, et al. Adaptive 861 
immune responses triggered by oxidative stress contribute to hepatic 862 
inflammation in NASH. Hepatology 2014;59:886-97 863 
53. D’Avila H, Melo RCN, Parreira GG, Werneck-Barroso E, Castro-Faria-Neto HC, 864 
Bozza PT. &lt;em&gt;Mycobacterium bovis&lt;/em&gt; Bacillus Calmette-Guérin 865 
Induces TLR2-Mediated Formation of Lipid Bodies: Intracellular Domains for 866 
Eicosanoid Synthesis In Vivo. The Journal of Immunology 2006;176:3087 867 
54. Kalinski P. Regulation of Immune Responses by Prostaglandin 868 
E&lt;sub&gt;2&lt;/sub&gt. The Journal of Immunology 2012;188:21 869 
55. Casar B, Badrock AP, Jimenez I, Arozarena I, Colon-Bolea P, Lorenzo-Martin 870 
LF, et al. RAS at the Golgi antagonizes malignant transformation through 871 
PTPRkappa-mediated inhibition of ERK activation. Nat Commun 2018;9:3595 872 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 24, 2020. . https://doi.org/10.1101/2020.06.23.166603doi: bioRxiv preprint 
 39 
56. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. 873 
Integrative analysis of complex cancer genomics and clinical profiles using the 874 
cBioPortal. Sci Signal 2013;6:pl1 875 
57. Mermel CH, Schumacher SE, Hill B, Meyerson ML, Beroukhim R, Getz G. 876 
GISTIC2.0 facilitates sensitive and confident localization of the targets of focal 877 
somatic copy-number alteration in human cancers. Genome Biology 878 
2011;12:R41 879 
58. Chen EY, Tan CM, Kou Y, Duan Q, Wang Z, Meirelles GV, et al. Enrichr: 880 
interactive and collaborative HTML5 gene list enrichment analysis tool. BMC 881 
Bioinformatics 2013;14:128 882 
59. Zhou Y, Zhou B, Pache L, Chang M, Khodabakhshi AH, Tanaseichuk O, et al. 883 
Metascape provides a biologist-oriented resource for the analysis of systems-884 
level datasets. Nature Communications 2019;10:1523 885 
60. Anaya J. OncoLnc: linking TCGA survival data to mRNAs, miRNAs, and 886 
lncRNAs. Peerj Comput Sci 2016 887 
61. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. 888 
ONCOMINE: a cancer microarray database and integrated data-mining platform. 889 
Neoplasia 2004;6:1-6 890 
 891 
  892 
.CC-BY-NC-ND 4.0 International license(which was not certified by peer review) is the author/funder. It is made available under a
The copyright holder for this preprintthis version posted June 24, 2020. . https://doi.org/10.1101/2020.06.23.166603doi: bioRxiv preprint 
 40 
Figure 1 DGAT1 amplification and up-regulation is associated with poor 893 
prognosis in melanoma  894 
(a) Patient survival from TCGA melanoma cohort (25% top vs 75% bottom by mRNA 895 
abundance, Y-axis) versus fold-change in mRNA expression of lipid metabolism genes 896 
in zebrafish tumors (X-axis). (b) Kaplan-Meier survival plot comparing melanoma 897 
patients based on expression of DGAT1 or DGAT2 (top 25% vs bottom 75%, TCGA 898 
data set). (c) DGAT1 relative gene expression in skin, nevi and melanoma tumors from 899 
indicated studies (Mean ± SD, n>3). (d) Protein expression of DGAT1 and Vinculin 900 
(loading control) (NHM- Normal Human Melanocytes). (e) Genetic alterations in the 901 
TCGA firehose legacy melanoma data set (counting only samples with CNV data) 902 
obtained from cBioPortal. (f) Schematic depicting human chromosome 8, the amplified 903 
arm (red), and known/putative melanoma oncogenes within this region. (g) G-Score of 904 
amplified regions of zebrafish chromosomes found in BRAFV600E-positive; tp53 mutant 905 
tumors indicating the position of presumed melanoma oncogene homologues. (h) 906 
Kaplan-Meier progression free survival plot comparing patients across multiple cancer 907 
types based on DGAT1 amplification. 908 
 909 
Figure 2 Dgat1 functions as an oncoprotein in zebrafish  910 
(a) DGAT1 amplification distribution in melanoma. (b) Kaplan-Meier plot of melanoma 911 
tumor nodule incidence in EGFP control or Dgat1a over-expressing animals on the tp53 912 
mutant; nacre genetic background. Representative images shown for EGFP and Dgat1a 913 
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positive animals at 54 and 76 weeks post-fertilisation respectively. (c) as for (b) but on 914 
the transgenic mitfa:BRAFV600E; tp53 mutant; nacre genetic background. Representative 915 
images are shown at 12 weeks post fertilisation. (d) as for (c) but on the transgenic 916 
mitfa:NRASG12D; tp53 mutant; nacre genetic background, also shown the effect of Dgat2 917 
over-expression. (e) Hematoxylin and eosin stained transverse sections of EGFP 918 
expressing or Dgat1a over-expressing melanoma on the transgenic mitfa:NRAS
G12D
; 919 
tp53 mutant; nacre genetic background. (f) Volcano plot of all genes from RNA-seq data 920 
from NRASG12D-positive EGFP-expressing (n=3) and from NRASG12D-positive Dgat1a 921 
over- expressing (n=5) tumors. Fold-change calculated comparing Dgat1a over-922 
expressing tumors to EGFP-expressing control tumors. (g) DGAT1 expression in TGCA 923 
pan cancer atlas RNA-seq data set filtered for NRASmut melanoma patients (upper). 924 
Venn diagram of significantly enriched gene sets after GSEA of significantly regulated 925 
genes comparing either NRASG12D-positive EGFP-expressing (n=3) and NRASG12D-926 
positive Dgat1a over-expressing (n=5) tumors or comparing DGAT1 mRNA high tumors 927 
(12/72) to the rest of the NRASmut TGCA dataset (60/72). (h) Selection of 11 pathways 928 
from the Venn diagram intersect is shown in the dot-plot. Dot size represents the P 929 
value.  930 
 931 
Figure 3 DGAT1 activity is required for maintenance of S6K signalling  932 
(a) Phospho-proteomics work flow (left). Enriched phosphorylated sites (WebGestalt) of 933 
up- (59) and down-regulated (96) phosphorylated proteins. Protein hub analysis of both 934 
up- and down-regulated phosphorylated proteins (right) (n=3). (b) Protein expression of 935 
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phospho-S6 and phospho-eEF2 following DGAT1 inhibitor treatment. (c) Confluency 936 
curves in cell lines transfected with DGAT1 targeting (007, 008, pool) or scrambled (SC) 937 
siRNAs (Mean, n=3) (above). Corresponding protein expression of DGAT1, phospho-S6 938 
and phospho-eEF2. (d) Confluency curves of parental 888MEL cells and 888mel cells 939 
following lentiviral transduction with a DGAT1 over-expression vector and clonal 940 
selection (Mean, n=3) (upper left). Corresponding crystal violet staining after 72 h 941 
growth (upper right). Corresponding protein expression of DGAT1 and phospho-S6 942 
(lower).  943 
 944 
Figure 4 DGAT1 supports S6K dependent melanoma cell growth  945 
(a) Heatmap of relative cell number determined by crystal violet following 72 h DGAT1 946 
inhibitor treatment (Mean, n>3). (b) Percentage of cells in S-phase using EdU 947 
incorporation following 24 h DGAT1 inhibitor treatment (Mean, n>3). (c) Protein 948 
expression in SKMEL105 cells of HA-tag, DGAT1 and phospho-S6 following both over 949 
expression of either GFP wild type S6 kinase or constitutively active S6-kinase and 950 
transfection with a DGAT1 targeting or scrambled siRNA (left). Confluency curves of 951 
SKMEL105 cells following both over-expression of S6 kinase or GFP and transfection 952 
with a DGAT1 targeting or scrambled siRNA (Mean, n=3) (right). (d) Quantification of 953 
the percentage of A375 cells in S-phase using EdU incorporation following over- 954 
expression of either S6 kinase, constitutively active S6 kinase or a GFP control 955 
with/without the presence of A922500 for 24 h (Mean ± SD, n>6).  (e) Confluency 956 
curves of 888MEL and clone 3 cells following treatment with/without 1 μM LY2584702 957 
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or 10 μM PF-4708671 determined by time-lapse microscopy using an Incucyte zoom 958 
system (left) (Mean ± SD, n=4). Corresponding protein expression of phospho-P70S6K, 959 
phospho-S6, S6 and DGAT1 (right). (f) Graph showing relative cell number determined 960 
by crystal violet following 72 h DGAT1 inhibitor treatment with cells grown in varying 961 
concentrations of foetal calf serum (FCS) (Mean, n>3). (g) Graph of relative cell number 962 
determined by crystal violet following 48 h DGAT1 inhibitor treatment under normoxic or 963 
hypoxic conditions (1% O2) with cells grown in varying concentrations of foetal calf 964 
serum (FCS) (relative to DMSO control for each condition) (Mean, n>3).  965 
 966 
Figure 5 DGAT1-driven lipid droplets act as caretakers of mitochondrial health  967 
(a) Lipidomic profiling using UHPLC-MS of NRASG12D-positive EGFP-expressing (n=6) 968 
and NRASG12D-positive Dgat1a-over-expressing (n=6) tumors showing the ratio of lipid 969 
species (annotated by MS/MS). (b) Representative images of 888MEL and Clone 3 970 
cells stained with BODIPY (left). Brightfield images of 888MEL parental cells and Clone 971 
3 DGAT1 over-expressing cells (middle). UHPLC-lipidomic analysis of 888MEL parental 972 
and Clone 3 DGAT1 over-expressing cells. Fold-change relative to 888MEL parental 973 
cells (right). TAG (triacyclglycerides), AcCa (acyl carnitine). (c) Quantification of the 974 
number of lipid droplets per cell using BODIPY staining following AZD3988 treatment 975 
(Mean ± SD, n>30). (d) UHPLC-lipidomic analysis of SKMEL105 cells following 976 
A922500 treatment. Fold-change relative to DMSO. TAG (triacyclglycerides), LPC 977 
(lysophosphatidycholine), AcCa (acyl carnitine), LPE (lysophosphatidylethanolamine). 978 
(e) Lipid species fold changes in SKMEL105 following 72 h A922500 treatment plotted 979 
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versus lipid species fold changes observed in clone 3 cells. f) Protein expression of 980 
phospho-AMPK and phospho-RAPTOR following A922500 treatment. (g) Oxygen 981 
consumption rate in A375 cells following 48 h A922500 treatment (upper). Basal 982 
respiration, ATP production and spare respiratory capacity were calculated (lower) 983 
(Mean ± SD, n=3). (h) Staining with JC-1 dye following A922500 treatment or following 984 
transfection with DGAT1 targeting siRNA. The percentage of cells that lost red J- 985 
aggregates was calculated by using 1 μM CCP as a positive control and comparing this 986 
to untreated cells to create two populations of cells for flow cytometry analysis (upper) 987 
(Mean ± SD, n>3). Protein expression of PINK1 and PARKIN following A922500 988 
treatment (lower).  989 
 990 
Figure 6 DGAT1 suppression generates ROS leading to mitochondrial lipid 991 
peroxidation  992 
(a) Total proteomics work flow (left). GEO of up-regulated proteins (114) ranked by 993 
combined score (wikipathways) or log adjusted P values (metascape) (right) (b). RT- 994 
qPCR analysis following A922500 treatment. Fold-change relative to DMSO (Mean, 995 
n=3). (c) Quantification of ROS levels using dihydroethidium fluorescence following 996 
A922500 treatment. Fold-change relative to DMSO (Mean, n>4). (d) Quantification of 997 
ROS levels using dihydroethidium fluorescence following transfection with either 998 
DGAT1 targeting siRNA or a scrambled control for 48-72 h. Fold-change calculated 999 
relative to scrambled control (Mean ± SD, n=3) (upper). Corresponding protein 1000 
expression of DGAT1 and phospho-AMPK (lower). (e) C11-Bodipy staining following 1001 
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A922500 treatment. Median fluorescence determined using FACS (Median ± SD, n>6). 1002 
(f) Mito-C11-Bodipy staining following A922500 treatment. Median fluorescence 1003 
determined using FACS (Median ± SD, n>6) (left) Representative histogram of B530/30- 1004 
A fluorescence (right). (g) Protein expression of DGAT1 and 4-Hydroxynonenal 1005 
following transfection with either DGAT1 targeting siRNA or a scrambled control for 48 1006 
h. (h) Protein expression of DGAT1 and 4-Hydroxynonenal following transfection with 1007 
either DGAT1 over-expression vector or an empty vector control for 48 h. (i) Protein 1008 
expression of Dgat1 , GFP and 4-Hydroxynonenal in NRAS
G12D
-positive GFP-1009 
expressing (n=4) and NRAS
G12D
-positive Dgat1a over-expressing (n=7) tumors.  1010 
 1011 
Figure 7 DGAT1 suppression triggers ROS induced apoptosis that is ameliorated 1012 
by SESN2  1013 
(a) Protein expression of SOD1, SOD2 and cleaved caspase3 following A922500 1014 
treatment. (b) Cleaved-caspase index following transfection of a DGAT1 targeting or 1015 
scrambled siRNA. At 24 h cells were treated with/without Tempol or Ebselen (Mean, 1016 
n=3) (lower). Corresponding protein expression of DGAT1 and cleaved caspase3 1017 
(upper). (c) Drug-dose response curve after 72 h treatment with ROS inducers (upper) 1018 
(Mean ± SD, n=3). Protein expression of cleaved-caspase3 and DGAT1 following 72 h 1019 
paraquat treatment (lower). (d) Relative cell number determined using crystal violet 1020 
staining following 48 h culture in indicated FCS serum levels under hypoxic (1% O2)  or 1021 
normoxic conditions (Mean ± SEM, n>3) (Upper). Corresponding protein expression of 1022 
SOD2, DGAT1 and cleaved caspase 3 under hypoxic (1% O2) conditions (lower). (e) 1023 
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Protein expression of SESN2 following A922500 treatment. (f) Confluency curves of 1024 
A375 cells transfected with either SESN2 or DGAT1 targeting or scrambled siRNA (left). 1025 
Corresponding cleaved-caspase index (right). Corresponding protein expression of 1026 
DGAT1 and Sestrin 2 (lower). (g) Quantification of ROS levels using dihydroethidium 1027 
fluorescence in A375 cells transfected with SESN2 targeting or scrambled siRNA (19, 1028 
20) followed by A922500 treatment for 24 h. Fold-change relative to scrambled control 1029 
(Mean ± SD, n>4). (h) Relative HMOX1 expression in A375 cells transfected with 1030 
SESN2 targeting or scrambled siRNA (19, 20) followed by A922500 treatment for 24 h. 1031 
Fold-change relative to DMSO (Mean ± SD, n=3).  1032 
 1033 
 1034 
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Figure 1 DGAT1 amplification and up-regulation is associated with poor prognosis in
melanoma
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Figure 2 Dgat1 functions as an oncoprotein in zebrafish
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Figure 4 DGAT1 supports S6K dependent melanoma cell growth
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Fluid shear stress and atherosclerosis




































































































































































































































































































































Figure 6 DGAT1 suppression generates ROS leading to mitochondrial lipid peroxidation
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Figure 7 DGAT1 suppression triggers ROS induced apoptosis that is ameliorated by SESN2
